PROTEOMICS – Clinical Applications最新文献_第9页

Proteomics and bioinformatics investigations to improve serological diagnosis of canine brucellosis. 蛋白质组学和生物信息学研究提高犬布鲁氏菌病的血清学诊断。

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-08-02 DOI: 10.1002/prca.202200116

Mirella Luciani, Ivanka Krasteva, Tiziana Di Febo, Fabrizia Perletta, Federica D'Onofrio, Fabrizio De Massis, Nicola D'Alterio, Flavio Sacchini, Manuela Tittarelli

{"title":"Proteomics and bioinformatics investigations to improve serological diagnosis of canine brucellosis.","authors":"Mirella Luciani, Ivanka Krasteva, Tiziana Di Febo, Fabrizia Perletta, Federica D'Onofrio, Fabrizio De Massis, Nicola D'Alterio, Flavio Sacchini, Manuela Tittarelli","doi":"10.1002/prca.202200116","DOIUrl":"10.1002/prca.202200116","url":null,"abstract":"Purpose: Brucella canis is pathogenic for dogs and humans. Serological diagnosis is a cost-effective approach for disease surveillance, but a major drawback of current serological tests is the cross-reactivity with other bacteria that results in false positive reactions. Development of indirect tests with improved sensitivity and specificity that use selected B. canis proteins instead of the whole antigen remain a priority.Experimental design: A western blotting assay was developed to define the serum antibody patterns associated to infection using a panel of positive and negative dog sera. B. canis positive sera recognized immunogenic bands ranging from 7 to 30 kDa that were then submitted to ESI-LC-MS/MS and analyzed by bioinformatics tools.Results: A total of 398 B. canis proteins were identified. Bioinformatics tools identified 16 non cytoplasmic immunogenic proteins predicted as non-homologous with the most important Brucella cross-reactive bacteria and nine B. canis proteins non-homologous to B. ovis; among the latter, one resulted non-homologous to B. melitensis. Data are available via ProteomeXchange with identifier PXD042682.Conclusions and clinical relevance: The western blotting test developed was able to distinguish between infected and non-infected animals and may serve as a confirmatory test for the serological diagnosis of B. canis. The mass spectrometry and in silico results lead to the identification of specific candidate antigens that pave the way for the development of more accurate indirect diagnostic tests.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2200116"},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment. 蛋白质组学在乳腺癌管理和药物再利用领域，以减轻治疗的复杂性。

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-05-31 DOI: 10.1002/prca.202300016

Rama N Behera, Vinod S Bisht, Kuldeep Giri, Kiran Ambatipudi

{"title":"Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment.","authors":"Rama N Behera, Vinod S Bisht, Kuldeep Giri, Kiran Ambatipudi","doi":"10.1002/prca.202300016","DOIUrl":"10.1002/prca.202300016","url":null,"abstract":"Breast cancer, a multi-networking heterogeneous disease, has emerged as a serious impediment to progress in clinical oncology. Although technological advancements and emerging cancer research studies have mitigated breast cancer lethality, a precision cancer-oriented solution has not been achieved. Thus, this review will persuade the acquiescence of proteomics-based diagnostic and therapeutic options in breast cancer management. Recently, the evidence of breast cancer health surveillance through imaging proteomics, single-cell proteomics, interactomics, and post-translational modification (PTM) tracking, to construct proteome maps and proteotyping for stage-specific and sample-specific cancer subtyping have outperformed conventional ways of dealing with breast cancer by increasing diagnostic efficiency, prognostic value, and predictive response. Additionally, the paradigm shift in applied proteomics for designing a chemotherapy regimen to identify novel drug targets with minor adverse effects has been elaborated. Finally, the potential of proteomics in alleviating the occurrence of chemoresistance and enhancing reprofiled drugs' effectiveness to combat therapeutic obstacles has been discussed. Owing to the enormous potential of proteomics techniques, the clinical recognition of proteomics in breast cancer management can be achievable and therapeutic intricacies can be surmountable.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2300016"},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9606883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The functional roles of m6A modification in prostate cancer. m6A修饰在前列腺癌症中的功能作用。

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-10-13 DOI: 10.1002/prca.202200108

Fa Zhang, Feng Chen, Chao Wang, Feng-Hai Zhou

{"title":"The functional roles of m6A modification in prostate cancer.","authors":"Fa Zhang, Feng Chen, Chao Wang, Feng-Hai Zhou","doi":"10.1002/prca.202200108","DOIUrl":"10.1002/prca.202200108","url":null,"abstract":"Prostate cancer (PCa) is the most prevalent malignancy of the male genitourinary system, and its etiology suggests that genetics is an essential risk factor for its development and progression, while exogenous factors may have an significant impact on this risk. Initial diagnosis of advanced PCa is relatively frequent, and androgen deprivation therapy (ADT) is the predominant standard of care for PCa and the basis for various novel combination therapy regimens, and is often required throughout the patient's subsequent treatment. Although diagnostic modalities and treatment options are evolving, some patients suffer from complications, including biochemical relapse, metastasis and treatment resistance. Mechanisms of PCa pathogenesis and progression have been the focus of research. N6-methyladenosine (m6A) is an RNA modification involved in cell physiology and tumor metabolism. It has been observed to affect the evolution of diverse cancers through the regulation of gene expression. Genes associated with m6A are prominent in PCa and are involved in multiple aspects of desmoresistant PCa occurrence, progression, PCa bone metastasis (BM), and treatment resistance. Here, we explore the role of m6A modifications in promoting PCa.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2200108"},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9687989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Masthead: Proteomics 6'23 刊头：蛋白质组学 6'23

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 DOI: 10.1002/prca.202370063

引用次数: 0

Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms. SARS-CoV-2疫苗接种个体血液中重组刺突蛋白的检测:可能的分子机制

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-08-31 DOI: 10.1002/prca.202300048

Carlo Brogna, Simone Cristoni, Giuliano Marino, Luigi Montano, Valentina Viduto, Mark Fabrowski, Gennaro Lettieri, Marina Piscopo

{"title":"Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms.","authors":"Carlo Brogna, Simone Cristoni, Giuliano Marino, Luigi Montano, Valentina Viduto, Mark Fabrowski, Gennaro Lettieri, Marina Piscopo","doi":"10.1002/prca.202300048","DOIUrl":"10.1002/prca.202300048","url":null,"abstract":"Purpose: The SARS-CoV-2 pandemic prompted the development and use of next-generation vaccines. Among these, mRNA-based vaccines consist of injectable solutions of mRNA encoding for a recombinant Spike, which is distinguishable from the wild-type protein due to specific amino acid variations introduced to maintain the protein in a prefused state. This work presents a proteomic approach to reveal the presence of recombinant Spike protein in vaccinated subjects regardless of antibody titer.Experimental design: Mass spectrometry examination of biological samples was used to detect the presence of specific fragments of recombinant Spike protein in subjects who received mRNA-based vaccines.Results: The specific PP-Spike fragment was found in 50% of the biological samples analyzed, and its presence was independent of the SARS-CoV-2 IgG antibody titer. The minimum and maximum time at which PP-Spike was detected after vaccination was 69 and 187 days, respectively.Conclusions and clinical relevance: The presented method allows to evaluate the half-life of the Spike protein molecule \"PP\" and to consider the risks or benefits in continuing to administer additional booster doses of the SARS-CoV-2 mRNA vaccine. This approach is of valuable support to complement antibody level monitoring and represents the first proteomic detection of recombinant Spike in vaccinated subjects.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2300048"},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10477408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Editorial Board: Proteomics 6'23 编辑委员会：蛋白质组学 6'23

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 DOI: 10.1002/prca.202370062

引用次数: 0

Identification of a potential prognostic plasma biomarker of acute ischemic stroke via untargeted LC-MS metabolomics. 通过非靶向LC-MS代谢组学鉴定急性缺血性卒中潜在预后血浆生物标志物。

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-06-27 DOI: 10.1002/prca.202200081

Ming-Hsiu Wu, Chiz-Tzung Chang, Yu-Ning Lin, Chao-Jung Chen

{"title":"Identification of a potential prognostic plasma biomarker of acute ischemic stroke via untargeted LC-MS metabolomics.","authors":"Ming-Hsiu Wu, Chiz-Tzung Chang, Yu-Ning Lin, Chao-Jung Chen","doi":"10.1002/prca.202200081","DOIUrl":"10.1002/prca.202200081","url":null,"abstract":"Purpose: Stroke is the sudden death of brain cells in a localized area due to an inadequate blood flow or blood vessel rupture, and it seriously affects the quality of life. The metabolite biomarkers are needed for predicting the functional outcome of acute ischemic stroke (AIS).Experimental design: To identify biomarkers for AIS, untargeted LC/MS metabolomics was performed on plasma samples from subjects with favorable prognosis (mRS ≤ 2) and unfavorable prognosis (mRS > 2). The identified markers were further absolutely quantified by a targeted MRM approach.Results: There were 10 upregulated and 26 downregulated markers. Among these candidates, one was successfully identified as glycocholic acid and then absolutely quantified in plasma samples. Glycocholic acid could discriminate between subjects with favorable and unfavorable prognosis with an area under the curve (AUC) of 0.68 and odds ratio of 5.88.Conclusions and clinical relevance: Glycocholic acid was identified as a potential plasma metabolite marker of non-progressive outcomes after ischemic stroke and could serve as predictive prognostic markers for clinical acute stroke outcomes.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2200081"},"PeriodicalIF":2.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Comparative proteomics of saliva of healthy and gingivitis individuals from Rio de Janeiro. 里约热内卢健康人和牙龈炎患者唾液的比较蛋白质组学。

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-09-01 Epub Date: 2023-02-17 DOI: 10.1002/prca.202200098

Carlos Vinicius Ferreira da Silva, Youssef Bacila Sade, Sandra Mara Naressi Scapin, Carina M da Silva-Boghossian, Eidy de Oliveira Santos

引用次数: 0

Mass spectrometry-based proteomic profiling of sonicate fluid differentiates Staphylococcus aureus periprosthetic joint infection from non-infectious failure: A pilot study. 基于质谱的超声液蛋白质组学分析区分金黄色葡萄球菌假体周围关节感染和非感染性失败：一项初步研究。

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-09-01 Epub Date: 2023-03-27 DOI: 10.1002/prca.202200071

Cody R Fisher, Kiran K Mangalaparthi, Kerryl E Greenwood-Quaintance, Matthew P Abdel, Akhilesh Pandey, Robin Patel

{"title":"Mass spectrometry-based proteomic profiling of sonicate fluid differentiates Staphylococcus aureus periprosthetic joint infection from non-infectious failure: A pilot study.","authors":"Cody R Fisher, Kiran K Mangalaparthi, Kerryl E Greenwood-Quaintance, Matthew P Abdel, Akhilesh Pandey, Robin Patel","doi":"10.1002/prca.202200071","DOIUrl":"10.1002/prca.202200071","url":null,"abstract":"Purpose: This pilot study aimed to use proteomic profiling of sonicate fluid samples to compare host response during Staphylococcus aureus-associated periprosthetic joint infection (PJI) and non-infected arthroplasty failure (NIAF) and identify potential novel biomarkers differentiating the two.Experimental design: In this pilot study, eight sonicate fluid samples (four from NIAF and four from S. aureus PJI) were studied. Samples were reduced, alkylated, and trypsinized overnight, followed by analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a high-resolution Orbitrap Eclipse mass spectrometer. MaxQuant software suite was used for protein identification, filtering, and label-free quantitation.Results: Principal component analysis of the identified proteins clearly separated S. aureus PJI and NIAF samples. Overall, 810 proteins were identified based on their detection in at least three out of four samples from each group; 35 statistically significant differentially abundant proteins (DAPs) were found (two-sample t-test p-values ≤0.05 and log2 fold-change values ≥2 or ≤-2). Gene ontology pathway analysis found that microbial defense responses, specifically those related to neutrophil activation, to be increased in S. aureus PJI compared to NIAF samples.Conclusion and clinical relevance: Proteomic profiling of sonicate fluid using LC-MS/MS differentiated S. aureus PJI and NIAF in this pilot study. Further work is needed using a larger sample size and including non-S. aureus PJI and a diversty of NIAF-types.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":"17 5","pages":"e2200071"},"PeriodicalIF":2.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509319/pdf/nihms-1890045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10271512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Masthead: Proteomics 5'23 刊头：蛋白质组学 5'23

IF 2 4区生物学

PROTEOMICS – Clinical Applications Pub Date : 2023-09-01 DOI: 10.1002/prca.202370053

引用次数: 0